VPIM
LXRX icon

Vanguard Personalized Indexing Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$85.7K Sell
54,965
-11,602
-17% -$16.9K ﹤0.01% 1970
2025
Q4 		$76.6K Hold
66,567
– – ﹤0.01% 1840
2025
Q3 		$89.9K Buy
66,567
+1,237
+2% +$1.4K ﹤0.01% 1837
2025
Q2 		$61.8K Buy
65,330
+28,594
+78% +$18.5K ﹤0.01% 1800
2025
Q1 		$16.9K Buy
36,736
+13,513
+58% +$8.53K ﹤0.01% 1791
2024
Q4 		$17.1K Buy
23,223
+3,301
+17% +$3.98K ﹤0.01% 1777
2024
Q3 		$31.3K Buy
19,922
+593
+3% +$1.06K ﹤0.01% 1717
2024
Q2 		$32.5K Buy
19,329
+3,844
+25% +$6.89K ﹤0.01% 1619
2024
Q1 		$37.2K Buy
15,485
+312
+2% +$670 ﹤0.01% 1579
2023
Q4 		$23.2K Buy
+15,173
New +$18K ﹤0.01% 1541

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Vanguard Personalized Indexing Management's LXRX Position: Q1 2026 in Review

Vanguard Personalized Indexing Management reduced its Lexicon Pharmaceuticals (LXRX) stake by 17% in Q1 2026, selling an estimated $16.9K and leaving 54,965 shares worth $85.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1970.

Vanguard Personalized Indexing Management first reported a position in LXRX in Q4 2023 and has held it in 10 quarters since. The position peaked at $89.9K in Q3 2025. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Vanguard Personalized Indexing Management held 54,965 shares of Lexicon Pharmaceuticals worth $85.7K as of Q1 2026.
  • Vanguard Personalized Indexing Management sold 11,602 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $16.9K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q1 2026, its #1970 holding.
  • Vanguard Personalized Indexing Management first reported a position in Lexicon Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • Vanguard Personalized Indexing Management's Lexicon Pharmaceuticals position peaked at $89.9K in Q3 2025.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q1 2026, filed 14 May 2026.